New drugs in development for the treatment of diabetes

Diabetes Spectrum

Volumn 22, Issue 2, 2009, Pages 92-106

  Levien, Terri L ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

189075; 6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; 8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ACZ 885; AJD 101; AKP 020; ALBIGLUTIDE; ALOGLIPTIN; ALS 2 0426; AMG 108; AMG 131; AMG 222; ASP 1941; AVE 0010; AVE 2268; AZD 6370; BALAGLITAZONE; BI 10773; BIM 51077; BMS 512148; BROMOCRIPTINE; CJC 1134 PC; CRX 401; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DM 71; DM 83; DUTOGLIPTIN; E 1 INT; EPRODISATE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GRC 8200; HE 3286; INCB 13739; INSULIN DERIVATIVE; INT 131; ISIS 113715; JNJ 39659100; KETOCONAZOLE; KGT 1681; KRP 104; LINAGLIPTIN; LIRAGLUTIDE; LY 2189265; MB 07803; MBX 2044; MDSC 0160; METAGLIDASEN; MGA 031; MITIGLINIDE; MK 0893; MK 0941; MONOCLONAL ANTIBODY CD3; MP 513; NETOGLITAZONE; NN 1250; NN 5401; NN 9535; ONO 5129; OTELIXIZUMAB; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PF 734200; PHX 1149; PLX 204; PPM 204; PROBUCOL SUCCINATE; PROTEIN INHIBITOR; R 1439; R 1579; R 1583; RECOMBINANT GLUTAMIC ACID DECARBOXYLASE 65; RECOMBINANT VACCINE; RHGAD 65; RHUPH 20; RIVOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SYR 472; TA 6666; TA 7284; TAGATOSE; TASPOGLUTIDE; TECHNOSPHERE INSULIN; TEPLIZUMAB; TRX 4; TT 223; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; YM 543; ZP 10;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE PRURITUS; INSULIN DEPENDENT DIABETES MELLITUS; METERED DOSE INHALER; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 66749130210     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.22.2.92     Document Type: Review

References (139)

1. Pharmaceutical Research and Manufacturers of America: New medicines database [database online]. Available from http://newmeds. phrma.org. Accessed 19 November 2008
2. Wolters Kluwer Health: Adis R&D Insight [database online]. Available from http://www. adisinsight.com. Accessed 19 November 2008
3. DiabesityDigest.com: Drugs in development [article online]. Available from http://www. diabesitydigest.com. Accessed 19 November 2008
4. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL: Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Reu 2008;2:CD006739
5. Novartis: Data show Galvus better tolerated by patients with type 2 diabetes, with no weight gain, a favorable cardiovascular profile and equal efficacy compared to widely-used TZDs [press release online]. Available from http://www.novartis.com/ newsroom. Accessed 3 December 2008
6. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M: (R)-8-(3-amino-piperidin-1-yl)-7-but-2- ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182, 2008
7. Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 30:513-527, 2008
8. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double- blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 30:499-512, 2008
9. Mekki Q, Fleck P, Wilson C, DeFronzo R: Efficacy and safety of alogliptin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise [abstract]. Diabetologia 51 (Suppl. 1):S344, 2008
10. Fleck P, Mekki Q, Kipnes M, Wilson C, Pratley R: Efficacy and safety of alogliptin and glyburide combination therapy in patients with type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S37, 2008
11. Rendell M, Rosenstock J, Gross J, Fleck P, Wilson C, Mekki Q: Addition of alogliptin to insulin therapy reduces HbA1c without increasing weight gain or hypoglycaemia in patients with type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S37-S38, 2008
12. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q: Alogliptin added to pioglitazone therapy improves glycaemic control in patients with type 2 diabetes without increasing weight gain or hypoglycaemia [abstract]. Diabetologia 51 (Suppl. 1):S343, 2008
13. Ellis G, Fleck P, Wilson C, Mekki Q, Nauck M: Alogliptin added to metformin therapy in patients with type 2 diabetes reduces HbA1c without changing weight or increasing gastrointestinal symptoms or hypoglycaemia [abstract]. Diabetologia 51 (Suppl. 1):S343-S344, 2008
14. Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, Gerstman M, Littlejohn TW, Schwartz SL, O'Farrell AM, Li X, Cherrington JM, Bennett C, Guler HP: The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diab Obes Metab 10:293-300, 2008
15. Phenomix: Safety and efficacy study of dutogliptin/PHX1149T to treat type 2 diabetes mellitus [online]. Available from http://clinicaltrials.gov/show/ NCT00690638 (NLM Identifier: NCT00690638). Accessed 3 December 2008
16. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA: The novel, potent, and selective DPP-IV inhibitor BI 1356 significantly lower HbA1c after only 4 weeks of treatment in patients with type 2 diabetes [abstract]. Diabetes 56 (Suppl. 1):A157-158, 2007
17. Boehringer Ingelheim Pharmaceuticals: Efficacy and safety of BI 1356 versus placebo in type 2 diabetic patients with insufficient glycemic control [article online]. Available from http://clinicaltrials.gov/ show/NCT00621140 (NLM Identifier: NCT00621140). Accessed 3 December 2008
18. Boehringer Ingelheim Pharmaceuticals: Efficacy vs. placebo as initial combination therapy with pioglitazone [article online]. Available from: http://clinicaltrials.gov/ show/NCT00641043 (NLM Identifier: NCT00641043). Accessed 3 December 2008
19. Boehringer Ingelheim Pharmaceuticals: A randomized, db, placebo-controlled study of BI 1356 for 18 weeks followed by a 34 week double-blind extension period (placebo patients switched to glimepiride) in type 2 diabetic patients for whom treatment with metformin is inappropriate [article online]. Available from http://clinicaltrials.gov/ show/NCT00740051 (NLM Identifier: NCT00740051). Accessed 3 December 2008
20. Boehringer Ingelheim Pharmaceuticals: Safety and efficacy of BI 1356 as monotherapy or in combination in type 2 DM [article online]. Available from http://clinicaltrials. gov/show/NCT00736099 (NLM Identifier: NCT00736099). Accessed 3 December 2008
21. Boehringer Ingelheim Pharmaceuticals: BI 1356 in combination with metformin and a sulphonylurea in type 2 diabetes [article online]. Available from http://clinicaltrials. gov/show/NCT00602472 (NLM Identifier: NCT00602472). Accessed 3 December 2008
22. Boehringer Ingelheim Pharmaceuticals: Efficacy and safety of BI 1356 vs. placebo added to metformin background therapy in patients with type 2 diabetes [article online]. Available from http://clinicaltrials. gov/show/NCT00601250 (NLM Identifier: NCT00601250). Accessed 3 December 2008
23. Boehringer Ingelheim Pharmaceuticals: Efficacy and safety of BI 1356 in combination with metformin in patients with type 2 diabetes [article online]. Available from http://clinicaltrials.gov/show/NCT00622284 (NLM Identifier: NCT00622284). Accessed 3 December 2008
24. Chen R, Pfutzner A, Jadzinsky M, Paz-Pacheco E, Xu Z, Allen E: Initial combination therapy with saxagliptin and metformin improves glycaemic control compared with either monotherapy alone in drug-naive patients with type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S38, 2008
25. Ravichandran S, Chacra AR, Tan GH, Apanovitch A, Chen R: Saxagliptin added to a sulfonylurea is safe and more effective than up-titrating a sulfonylurea in patients with type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S342, 2008
26. Allen E, Hollander P, Li J, Chen R: Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S342-S343, 2008
27. Rosenstock J, Sankoh S, List JF: Glucose- lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10:376-386, 2008
28. AstraZeneca, Bristol-Myers Squibb: Evaluate efficacy and safety of saxagliptin in adult patients with type 2 diabetes inadequate glycemic control [article online]. Available from http://clinicaltrials.gov/ show/NCT00698932 (NLM Identifier: NCT00698932). Accessed 15 December 2008
29. AstraZeneca, Bristol-Myers Squibb: 18-Week add-on to metformin comparison of saxagliptin and sitagliptin [article online]. Available from: http://clinicaltrials. gov/show/NCT00666458 (NLM Identifier: NCT00666458). Accessed 15 December 2008
30. AstraZeneca, Bristol-Myers Squibb: Evaluate efficacy and safety of saxagliptin in combination with metformin in adult patients with type 2 diabetes [article online]. Available from http://clinicaltrials.gov/ show/NCT00661362 (NLM Identifier: NCT00661362). Accessed 15 December 2008
31. AstraZeneca, Bristol-Myers Squibb: Safety and efficacy study of subjects that are taking saxagliptin added onto metformin XR compared to subjects taking Metformin XR alone [article online]. Available from http:// clinicaltrials.gov/ show/NCT00683657 (NLM Identifier: NCT00683657). Accessed 15 December 2008
32. AstraZeneca, Bristol-Myers Squibb: Safety and efficacy study of saxagliptin added to insulin alone or to insulin taken with metformin [article online]. Available from http:// clinicaltrials.gov/show/NCT00757588 (NLM Identifier: NCT00757588). Accessed 15 December 2008
33. AstraZeneca, Bristol-Myers Squibb: Treatment effect of saxagliptin compared with placebo in patients with type 2 diabetes and renal impairment [article online]. Available from http://clinicaltrials.gov/ show/NCT00614939 (NLM Identifier: NCT00614939). Accessed 15 December 2008
34. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE: Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10:675-682, 2008
35. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE: Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10:1114-1124, 2008
36. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S: Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 76:132-138, 2007 (Pubitemid 46240373)
37. Pratley RE, Schweizer A, Rosenstock J, Couturier A, Pi-Sunyer FX, Dejager S, Banerji MA: Management of type 2 diabetes in treatment-naive elderly patients. Diabetes Care 30:3017-3022, 2007
38. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Wang Y, Foley JE: Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 25:435-441, 2008
39. Schweizer A, Couturier A, Foley JE, Dejager S: Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 24:955-961, 2007 (Pubitemid 47301637)
40. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S: Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 9:175-185, 2007 (Pubitemid 46206561)
41. Rosenstock J, Mills D, Baron MA, Schweizer A, Dejager S: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 30:217-223, 2007
42. Bosi E, Rochotte E, Camisasca RP, Garber AJ, Collober C: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30:890-895, 2007 (Pubitemid 46556583)
43. Ahren B, Mills D, Gomis R, Schweizer A, Standi E: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880, 2004 (Pubitemid 39565052)
44. Bolli G, Dotta F, Rochotte E, Cohen SE: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 10:82-90, 2008 (Pubitemid 350302434)
45. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, Couturier A, Baron MA: Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab10:1047-1056, 2008
46. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S: Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9:166-174, 2007 (Pubitemid 46206560)
47. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S: Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50:1148-1155, 2007 (Pubitemid 46701545)
48. Novartis: Safety and tolerability of vildagliptin versus sitagliptin in patients with type 2 diabetes and severe renal insufficiency [article online]. Available from http://clinicaltrials. gov/show/NCT00616811 (NLM Identifier: NCT00616811). Accessed 15 December 2008
49. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Bush MA, Albiglutide Study Group: Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrin Metab 93:4810-4817, 2008
50. Rosenstock J, Ratner RE, Botka G: Dose range effects of the new once daily GLP-1 receptor agonist AVE0010 added to metformin in type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S66, 2008
51. Sanofi-Aventis: GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation in monotherapy (GETGOAL-MONO) [article online]. Available from http://clinicaltrials. gov/show/NCT00688701 (NLM Identifier: NCT00688701). Accessed 4 December 2008
52. Sanofi-Aventis: GLP-1 agonist AVE0010 (morning or evening) in patients with type 2 diabetes for glycemic control and safety evaluation on top of metformin (GETGOAL-M) [article online]. Available from http://clinicaltrials. gov/show/NCT00712673 (NLM Identifier: NCT00712673). Accessed 4 December 2008
53. Sanofi-Aventis: GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-F1) [article online]. Available from http://clinicaltrials. gov/show/NCT00763451 (NLM Identifier: NCT00763451). Accessed 4 December 2008
54. Sanofi-Aventis: GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of sulfonylurea (GETGOAL-S) [article online]. Available from http://clinicaltrials. gov/show/NCT00713830 (NLM Identifier: NCT00713830). Accessed 4 December 2008
55. Sanofi-Aventis: GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of basal insulin (GETGOAL-L) [article online]. Available from http://clinicaltrials. gov/show/NCT00715624 (NLM Identifier: NCT00715624). Accessed 4 December 2008
56. Sanofi-Aventis: GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycemic control and safety evaluation, on top of pioglitazone (GETGOAL-P) [article online]. Available from http://clinicaltrials. gov/show/NCT00763815 (NLM Identifier: NCT00763815). Accessed 4 December 2008
57. Sanofi-Aventis: GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycemic control and safety evaluation, on top of metformin (GETGOAL-X) [article online]. Available from http://clinicaltrials. gov/show/NCT00707031 (NLM Identifier: NCT00707031). Accessed 4 December 2008
58. Kim D, Trautman M, MacConell L, Fineman M, Zhuang D, Taylor K, Kothare PA: Effects of once-weekly dosing of a long- acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493, 2007 (Pubitemid 46871159)
59. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250, 2008
60. Buse J, Drucker D, Taylor K, Kim T, Wilhelm K, Kendall D, Trautmann M, Zhuang D, Porter L: Exenatide once weekly elicits sustained glycaemic control and weight loss over 52 weeks [abstract]. Diabetologia 51 (Suppl. 1):S67, 2008
61. Marre M, Shaw J, Brandle M, Wan Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le-Thi TD, Colagiuri S: Liraglutide added to a sulphonylurea (SU) offers significantly better glycaemic control and favourable weight change compared with rosiglitazone and SU combination therapy in T2D [abstract]. Diabetologia 51 (Suppl. 1):S359, 2008
62. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olivera-Alvarez I, Hale PM, Zdravkovic M, Bode B, LEAD-3 (Mono) Study Group: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481, 2008
63. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR, LEAD-2 Study Group: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 32:84-90, 2009
64. Zinman B, Gerich J, Buse J, Lewin A, Schwartz SL, Raskin P, Hale PM, Zdravkovic M, Blonde L: Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial [abstract]. Diabetologia 51 (Suppl. 1):S359-S360, 2008
65. Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic NM, Antic S, Zdravkovic M, Ravn GM, Simo R: Significantly better glycemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S68, 2008
66. Eli Lilly and Co., United Biosource Corporation, Tessella Inc., Berry Consultants LLC: A study of LY2189265 compared to sitagliptin in patients with type 2 diabetes mellitus on metformin [article online]. Available from http://clinicaltrials.gov/ show/NCT00734474 (NLM Identifier: NCT00734474). Accessed 4 December 2008
67. Ratner R, Nauck M, Asnagi V, Berria R, Cressier F, Boldrin M, Balena R: Safety and tolerability of high doses of the long acting, human GLP1 analogue R1583 in diabetic subjects treated with metformin: a double- blind, placebo-controlled phase 2 study [abstract]. Diabetes 57 (Suppl. 1):A3, 2008
68. Balena R, Ratner R, Berria R, Asnaghi V, Grant R, Snaith J, Boldrin M, Nauck M: Eight weeks of treatment with the long acting, human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: a double- blind placebo-controlled phase 2 study [abstract]. Diabetes 57 (Suppl. 1):A33, 2008
69. Hoffmann-La Roche: A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with diet and exercise [article online]. Available from http:// clinicaltrials.gov/ show/NCT00744926 (NLM Identifier: NCT00744926). Accessed 4 December 2008
70. Hoffmann-La Roche: A study of taspoglutide versus placebo for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone [article online]. Available from http://clinicaltrials.gov/show/NCT00744367 (NLM Identifier: NCT00744367). Accessed 4 December 2008
71. Hoffmann-La Roche: A study of taspoglutide versus exenatide for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin, thiazolidinedione or a combination of both [article online]. Available from http:// clinicaltrials.gov/show/NCT00717457 (NLM Identifier: NCT00717457). Accessed 4 December 2008
72. Hoffmann-La Roche: A study of the safety, tolerability and effect on glycemic control of taspoglutide versus insulin glargine in insulin naïve type 2 diabetic patients inadequately controlled with metformin plus sulphonylurea [article online]. Available from http:// clinicaltrials.gov/show/ NCT00755287 (NLM Identifier: NCT00755287). Accessed 4 December 2008
73. Hoffmann-La Roche: A study of taspoglutide versus sitagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin [article online]. Available from http://clinicaltrials. gov/show/NCT00754988 (NLM Identifier: NCT00754988). Accessed 4 December 2008
74. Chang F, Jaber LA, Berlie HD, O'Connell MB: Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 41:973-983, 2007 (Pubitemid 46917624)
75. Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM: Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-γ) agonist balaglitazone. Eur J Pharmacol 506:173-179, 2008
76. Zhang F, Lavan BE, Gregoire FM: Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Research 2007 electronically published (doi:10.1144/2007/32696)
77. Rheoscience A/S: Efficacy and safety of treatment with balaglitazone in type 2 diabetes patients on stable insulin therapy (BALLET) [article online]. Available from http://clinicaltrials.gov/show/NCT00515632 (NLM Identifier: NCT00515632). Accessed 12 December 2008
78. Daiichi Sankyo Inc.: Randomized, double- blind active comparator-controlled study of rivoglitazone in type 2 diabetes mellitus [article online]. Available from http:// clinicaltrials.gov/show/NCT00484198 (NLM Identifier: NCT00484198). Accessed 12 December 2008
79. Truitt K, Chou HS, Wang A, Walker JR, Rosenstock J: A randomized, multiple-dose, placebo-controlled comparative study of rivoglitazone (Rivo, CS-011) and open-label pioglitazone (Pio) in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 57 (Suppl. 1):A130-131, 2008
80. Chou HS, Wang A, Walker JR, Truitt K, Rosenstock J: A randomized, placebo- controlled, 26-week dose response study of rivoglitazone (RIVO, CS-011) versus pioglitazone (PIO) in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 57 (Suppl. 1):A87, 2008
81. Jabbour SA, Goldstein BJ: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 62:1279-1284, 2008
82. List JF, Woo V, Morales E, Tang Q, Fiedorek FT: Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S22-S23, 2008
83. Woo V, List JF, Morales E, Tang W, Fiedorek FT: Dapagliflozin-induced glucosuria is accompanied by weight loss in type 2 diabetes patients [abstract]. Diabetologia 51 (Suppl. 1):S317-S318, 2008
84. Bristol-Myers Squibb, AstraZeneca: Safety and efficacy of dapagliflozin as monotherapy in subjects with type 2 diabetes [article online]. Available from http://clinicaltrials. gov/show/NCT00736879 (NLM Identifier: NCT00736879). Accessed 12 December 2008
85. Bristol-Myers Squibb, AstraZeneca: A Phase III study of BMS-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled with diet and exercise [article online]. Available from http://clinicaltrials. gov/show/NCT00528372 (NLM Identifier: NCT00528372). Accessed 12 December 2008
86. Bristol-Myers Squibb, AstraZeneca: Efficacy and safety of dapagliflozin in combination with metformin in type 2 diabetes patients [article online]. Available from http:// clinicaltrials.gov/show/NCT00660907 (NLM Identifier: NCT00660907). Accessed 12 December 2008
87. Bristol-Myers Squibb, AstraZeneca: An efficacy & safety study of BMS-512148 in combination with metformin extended release tablets [article online]. Available from http:// clinicaltrials.gov/show/NCT00643851 (NLM Identifier: NCT00643851). Accessed 12 December 2008
88. Bristol-Myers Squibb, AstraZeneca: A phase III study of BMS-512148 (dapagliflozin) in patients with type 2 diabetes who are not well controlled on metformin alone [article online]. Available from http://clinicaltrials. gov/show/NCT00528879 (NLM Identifier: NCT00528879). Accessed 12 December 2008
89. AstraZeneca, Bristol-Myers Squibb: Efficacy and safety of dapagliflozin in combination with glimepiride (a sulphonylurea) in type 2 diabetes patients [article online]. Available from http://clinicaltrials. gov/show/NCT00680745 (NLM Identifier: NCT00680745). Accessed 12 December 2008
90. Bristol-Myers Squibb, AstraZeneca: Add-on to thiazolidinedione (TZD) failures [article online]. Available from http://clinicaltrials. gov/show/NCT00683878 (NLM Identifier: NCT00683878). Accessed 12 December 2008
91. AstraZeneca, Bristol-Myers Squibb: Efficacy and safety of dapagliflozin, added to therapy of patients with type 2 diabetes with inadequate glycemic control on insulin [article online]. Available from http:// clinicaltrials.gov/ show/NCT00673231 (NLM Identifier: NCT00673231). Accessed 12 December 2008
92. Sinclair AJ, Whisnant JK: A randomized, double-blind trial comparing a new, rapid onset and short duration insulin secretagogue, mitiglinide, to acarbose for the treatment of elderly patients with type 2 diabetes mellitus (T2DM) [abstract]. Diabetes 56 (Suppl. 1):A563, 2007
93. O'Brien R, Scott RS, Whisnant JK: Synergistic efficacy by addition of mitiglinide, a new rapid onset and short duration insulin secretagogue, to standard metformin for type 2 diabetes mellitus (T2DM) in a large randomized, double-blind trial [abstract]. Diabetes 56 (Suppl. 1):A553, 2007
94. Yoshihara T, Kumashiro N, Kanazawa Y, Mita T, Sakurai Y, Kawai J, Abe M, Motojima K, Hara K, Yamazaki Y, Kanazawa A, Miwa S, Sato F, Kanno R, Shimizu T, Sakai K, Uchino H, Watada H, Tanaka Y, Kawamori R, Hirose T: Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 53:67-72, 2006
95. Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T: Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 54:163-166, 2007 (Pubitemid 46481685)
96. Yamada S, Watanabe M, Funae O, Atsumi Y, Suzuki R, Yajima K, Nakamura Y, Kawai T, Oikawa Y, Shimada A: Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. Intern Med 46:1893-1897, 2007
97. Elixir Pharmaceuticals: Mitiglinide in combination with metformin vs. metformin alone in patients with type 2 diabetes mellitus [article online]. Available from http:// clinicaltrials.gov/show/NCT00519142 (NLM Identifier: NCT00519142). Accessed 12 December 2008
98. Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B, 0008 Study Group: Efficacy and safety of technosphere inhaled insulin compared with technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 31:2177-2182, 2008
99. Boss AH, Baughman RA, Evans SH, Firsov I, Kramer DA, Richardson P: A 3 month comparison in type 1 diabetes of inhaled Technosphere®/insulin (TI) to sc administered rapid-acting insulin analogue (RAA) as prandial insulin in a basal/prandial regimen [abstract]. Diabetes 55 (Suppl. 1):A97, 2006
100. Rave K, Pfutzner A, Heise T, Boss AH: Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 30:2307-2308, 2007 (Pubitemid 47359038)
101. Tu N, Kramer D, Baughman R: Inhaled Technosphere®/insulin improves glycemic control without weight gain [abstract]. Diabetes 56 (Suppl. 1):A125, 2007
102. Mannkind Corporation: Efficacy and safety of prandial inhalation of Technosphere/insulin in combination with metformin or Technosphere/insulin alone versus 2 oral anti-diabetic agents in subjects with type 2 diabetes [article online]. Available from http://clinicaltrials.gov/show/NCT00332488 (NLM Identifier: NCT00332488). Accessed 12 December 2008
103. Mannkind Corporation: Safety and efficacy of Technosphere® insulin inhalation powder and Lantus® compared to Humalog® and Lantus® over 16-weeks [article online]. Available from http:// clinicaltrials.gov/show/ NCT00700622 (NLM Identifier: NCT00700622). Accessed 12 December 2008
104. Mannkind Corporation: Efficacy and safety in subjects with type 2 diabetes receiving subcutaneous basal insulin and prandial inhalation of Technosphere/insulin versus subcutaneous premixed insulin therapy over a 52-week treatment period and a 4-week follow-up [article online]. Available from http://clinicaltrials.gov/show/NCT00309244 (NLM Identifier: NCT00309244). Accessed 12 December 2008
105. Mannkind Corporation: Efficacy & safety of inhaled insulin in type 1 diabetes [article online]. Available from http://clinicaltrials. gov/show/NCT00308308 (NLM Identifier: NCT00308308). Accessed 12 December 2008
106. Baughman RA, Evans SH, Boss AH, Firsov I, Harris R, Ren H, Richardson PC: Technosphere insulin does not affect pulmonary function in a 6 month study of patients with type 2 diabetes [abstract]. Diabetologia 49 (Suppl. 1):117, 2006
107. Mannkind Corporation: Safety of inhaled insulin with type 1 and type 2 diabetes [article online]. Available from http:// clinicaltrials.gov/show/ NCT00308737 (NLM Identifier: NCT00308737). Accessed 12 December 2008
108. Modi P, Mihic M, Lewin A: The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ system. Diabetes Metab Res Rev 18 (Suppl. 1):S38-S42, 2002 (Pubitemid 34411299)
109. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom AL: Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes. Diabetes Technol Ther 9:372-376, 2007 (Pubitemid 47340087)
110. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J: Comparison of pre-prandial s.c. regular insulin vs prandial oral insulin in adult type-1 DM subjects receiving basal s.c. twice daily isophan insulin (NPH) [abstract]. Diabetes 56 (Suppl. 1):0474-P, 2007
111. Guevara-Aguirre J, Guevara-Aguiree M, Saavedra J, Rosenbloom A, Bernstein G: Insulin analogue (basal + pre-prandial injection) vs. human insulin (basal injection + prandial oral insulin (Generex Oral-lynTM) in type-1 diabetes mellitus: a 372-day comparison [abstract]. Diabetes 57 (Suppl. 1):A559-A560, 2008
112. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G: 6-month safety and efficacy of lunch-time oral insulin in juvenile type-1 DM subjects receiving basal glargine insulin and pre-breakfast and pre-dinner S.C. regular insulin [abstract]. Diabetes 56 (Suppl. 1):2760-PO, 2007
113. Generex Biotechnology Corp.: Active comparator study of Generex Oral-LynTM spray and injected human insulin [article online]. Available from http://clinicaltrials. gov/show/NCT00668850 (NLM Identifier: NCT00668850). Accessed 12 December 2008
114. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T, Pfutzner A, Heinemann L: A novel insulin formulation with a more rapid onset of action. Diabetologia 51:1602-1606, 2008
115. Steiner S, Hompesch M, Pohl R, Flacke F, Pfuetzner A, Simms PV, Heinemann L: Pharmacokinetics and pharmacodynamics of insulin VIAjectTM and regular human insulin when injected subcutaneously directly before a meal in patients with type 1 diabetes [abstract]. Diabetes 56 (Suppl. 1):A9, 2007
116. Biodel: An open label, multi-center, randomized, parallel group study comparing the efficacy and safety of insulin VIAjectTM and regular human insulin in patients with type 1 diabetes mellitus [article online]. Available from http://clinicaltrials. gov/show/NCT00542724 (NLM Identifier: NCT00542724). Accessed 12 December 2008
117. Biodel: An open label, multi-center, randomized, parallel group study comparing the efficacy and safety of insulin VIAjectTM and regular human insulin in patients with type 2 diabetes mellitus [article online]. Available from http://clinicaltrials. gov/show/NCT00542633 (NLM Identifier: NCT00542633). Accessed 12 December 2008
118. Scranton RE, Gaziano JM, Rutty D, Ezrokhi M, Cincotta A: A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either CyclosetTM or placebo. BMC Endocr Dis 2007; 7:3 electronically published (doi:10.1186/1472-6823-7-3) (Pubitemid 47161742)
119. Pijl H, Pipek R, Ohashi S, Iozzo P, Matsuda M, Lancaster JL, Cincotta AH, DeFronzo RA: Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 23:1154-1161, 2000 (Pubitemid 30616805)
120. Cincotta AH, Gaziano JM, Ezrokhi M, Scranton R: Cycloset (quick-release bromocriptine mesylate), a novel centrally acting treatment for type 2 diabetes [abstract]. Diabetologia 51 (Suppl. 1):S22, 2008
121. Forman D, Vaickus L, Rosenzweig M: Otelixizumab induces expansion of human CD4+FoxP3+ cells in vitro and in vivo [abstract]. Diabetes 57 (Suppl. 1):A154, 2008
122. Tolerx Inc.: Phase 3 trial of otelixizumab for adults with newly diagnosed type 1 (autoimmune) diabetes mellitus: DEFEND-1 [article online]. Available from http:// clinicaltrials.gov/show/NCT00678886 (NLM Identifier: NCT00678886). Accessed 12 December 2008
123. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Effects of recombinant human glutamic acid decarboxylase (rhGAD65) formulated in alum (GAD-alum) on the progression of type 1 diabetes in new onset subjects [article online]. Available from http://clinicaltrials. gov/show/NCT00529399 (NLM Identifier: NCT00529399). Accessed 12 December 2008
124. Agardh CD, Cilio CM, Lethagen AL, Lynch K, Leslie RDG, Palmer M, Harris RA, Robertson JA, Lernmark A: Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 19:238-246, 2005 (Pubitemid 40910206)
125. Agardh CD, Lethagen A, Cilio CM, Lynch K, Palmer M, Leslie DRG, Harris RA, Robertson JA, Lernmark A: Beta cell function and metabolic control during two years of follow-up after GAD65 dose-escalation immunomodulation in adult-onset autoimmune diabetes [abstract]. Diabetes 56 (Suppl. 1):1173-P, 2006
126. Diamyd Therapeutics AB: A phase III study to investigate the impact of Diamyd in patients newly diagnosed with type 1 diabetes (USA) [article online]. Available from http:// clinicaltrials.gov/show/NCT00751842 (NLM Identifier: NCT00751842). Accessed 12 December 2008
127. Franks AM, Gardner SF: AGI-1067: a novel vascular protectant for prevention of restenosis. Ann Pharmacother 40:66-73, 2006 (Pubitemid 43221477)
128. Tardif JC, McMurray JJV, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA, Aggressive Reduction of Inflammation Stops Events (ARISE) Trial Investigators: Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371:1761-1768, 2008
129. Klug E, Pfeffer MA, McMurray JJ, Fleming AG, Long WA, Small R, Tardif JC: AGI-1067 improves glycemic control when added to current regimens in patients with type 2 diabetes [abstract]. Diabetes 57 (Suppl. 1):A132, 2008
130. AtheroGenics: ANDES-AGI-1067 as a novel antidiabetic agent evaluation study [article online]. Available from http:// clinicaltrials.gov/show/ NCT00525577 (NLM Identifier: NCT00525577). Accessed 12 December 2008
131. AtheroGenics, Inc.: AtheroGenics reports positive results from ANDES phase 3 clinical trial of AGI-1067 in type 2 diabetes [press release online]. Atlanta, Ga., AtheroGenics, Inc., July 31,2008. Available from www. atherogenics.com. Accessed 15 December 2008
132. Lu Y, Levin GV, Donner TW: Tagatose, a new antidiabetic and obesity control drug. Diabetes Obes Metab 10:109-134, 2008
133. Donner TW, Wilber JF, Ostrowski D: D-tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obes Metab 1:285-291, 1999
134. Donner TW: The metabolic effects of dietary supplementation with D-tagatose in patients with type 2 diabetes [abstract]. Diabetes 55 (Suppl. 1):A110, 2006
135. BioSpherix, Spherix: A clinical study to evaluate the effect of Naturlose (tagatose) [article online]. Available from http:// clinicaltrials.gov/show/ NCT00451477 (NLM Identifier: NCT00451477). Accessed 12 December 2008
136. Pillemer SR, Carlin D, Protégé Trial Group: Protégé Trial: Teplizumab, a monoclonal antibody, for treatment of type 1 diabetes mellitus [abstract]. Diabetes 57 (Suppl. 1):A585-A586, 2008
137. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698, 2002 (Pubitemid 34547482)
138. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA: A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769, 2005 (Pubitemid 40770766)
139. MacroGenics, Juvenile Diabetes Research Foundation (JDRF): The Protégé Study: clinical trial of MGA031 in children and adults with recent-onset type 1 diabetes mellitus [article online]. Available from http://clinicaltrials.gov/show/NCT00385697 (NLM Identifier: NCT00385697). Accessed 12 December 2008